Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Lanlan Pang

6PUBLICATIONS

28CO-AUTHORS

Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Disease surveillanceMajor global burdens of disease

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (6)

Sort by Publication Date:

|Apr 05, 2024

Co-occurring EGFR p.E709X Mutation Mediates Primary Resistance to the Third-Generation EGFR-TKIs in EGFR p.G719X-Mutant Patients with Advanced NSCLC.

Lanlan Pang, Yihua Huang, Weitao Zhuang

|Jan 12, 2023

Exploration of immunotherapy in advanced pulmonary lymphoepithelioma-like carcinoma.

Lan-Lan Pang, Jun Liao, Yi-Hua Huang

|Sep 07, 2022

Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I.

Lan-Lan Pang, Jia-Di Gan, Jia-Rong Tan

|Jun 13, 2022

Investigation of the optimal platinum-based regimen in the postoperative adjuvant chemotherapy setting for early-stage resected non-small lung cancer: a Bayesian network meta-analysis.

Lan-Lan Pang, Jia-Di Gan, Yi-Hua Huang

|Mar 24, 2022

Role of Telemedicine in Inflammatory Bowel Disease: Systematic Review and Meta-analysis of Randomized Controlled Trials.

Lanlan Pang, Hengyu Liu, Zhidong Liu

|Oct 26, 2020

The effects of telemedicine on the quality of life of patients with lung cancer: a systematic review and meta-analysis.

Lanlan Pang, Zefu Liu, Sheng Lin

Pageof 1

Frequent Collaborators

3 joint publications

Yihua Huang

1 joint publications

Chongxiang Chen

1 joint publications

Hengyu Liu

1 joint publications

Zhidong Liu

1 joint publications

Jinyu Tan

1 joint publications

Long-Yuan Zhou

1 joint publications

Yun Qiu

1 joint publications

Xiaoqing Lin

1 joint publications

Jinshen He

1 joint publications

Xuehua Li

Frequent Collaborators

3 joint publications

Yihua Huang

1 joint publications

Chongxiang Chen

1 joint publications

Hengyu Liu

1 joint publications

Zhidong Liu

Top Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Published on : Aug 11, 2017

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on : Feb 24, 2023

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos

Top Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells <em>In Vitro</em> with a 2-step Dose-escalation Procedure

Published on : Aug 11, 2017

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on : Feb 24, 2023

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

See more related videos